[1] Cardiovascular diseases (CVDs)[S/OL].(2017-05-17)[2021-01-18].https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). [2] Krzysztof J, Piotr J, Kosior DA.PCSK9 inhibitors-from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade[J]. Archives of Medical Science Ams, 2017, 13: 914-929. [3] Navarese EP, Robinson JG, Kowalewski M, et al.Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis[J]. JAMA, 2018, 319(15): 1566. [4] Zhang H, Plutzky J, Skentzos S, et al.Discontinuation of statins in routine care settings: a cohort study[J]. Annals of Internal Medicine, 2013,158(7): 526-34. [5] Sabatine MS.PCSK9 inhibitors: clinical evidence and implemen-tation[J]. Nat Rev Cardiol, 2019, 16(3): 155-165. [6] Seidah NG.Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies[J].Current Pharmaceutical Design, 2013, 19(17): 3161-3172. [7] Melendez QM, Krishnaji ST, Wooten CJ, et al. Hypercholesterolemia: the role of PCSK9[J]. Archives of Biochemistry and Biophysics, 2017, 625-626: 39-53. [8] FDA. What is openFDA?[S/OL]. (2021-01-18)[2021-01-18].https://open.fda.gov/about/. [9] Geng YY, Cai J, Xie H, et al.Adverse drug reactions of fentanyl citrate and sufentanil citrate based on openFDA[J]. Central South Pharmacy(中南药学), 2020, 18(4): 706-710. [10] Meng L, Tang XW, Ji HH.Mining and evaluation of statin-associated adverse events signals: data mining of the public version of the OpenFDA adverse event reporting system[J]. Chinese Journal of New Drugs(中国新药杂志), 2019, 28(2): 120-124. [11] FDA. What adverse reactions are frequently reported?[S/OL]. (2021-05-07)[2021-05-07].https://open.fda.gov/apis/drug/event/example-api-queries/. [12] Fierce Pharma Amgen escalates PCSK9 pricing war with permanent 60% price cut on Repatha[S/OL].(2019-10-25) [2021-01-18].https://www.fiercepharma.com/pharma/cholesterol-war-escalates-as-amgen-makes-60-price-cut-repatha-permanent. [13] Xing WQ, Wu JR, Mao QR.Self-reporting of adverse drug reactions by inpatients based on internet plus big data technology[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(7): 408-411. [14] Ferri N, Ruscica M, Coggi D, et al.Sex-specific predictors of PCSK9 levels in a European population: the IMPROVE study[J]. Atherosclerosis, 2020, 309: 39-46. [15] Cui Q, Ju X, Yang T, et al.Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population[J]. Atherosclerosis, 2010, 213(2): 632-636. [16] Blom DJ, Harada-Shiba M, Rubba P, et al.Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial[J]. J Am Coll Cardiol, 2020, 76(2): 131-142. [17] Zong X Wang YL. On OpenFDA and enlightenments for data management of Food and Drug Administration in China[J]. Chinese Pharmaceutical Affairs(中国药事), 2017, 31(9): 976-979. [18] Ling T, Xu RJ, Ge WH.Comparative analysis of adverse drug reactions of rivaroxaban and apixaban based on OpenFDA[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 1818, 780-783. |